Upgrade to SI Premium - Free Trial

Form SCHEDULE 13G Eloxx Pharmaceuticals, Filed by: Stonepine Capital Management, LLC

June 16, 2026 6:05 PM





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: The securities beneficially owned by the reporting persons consist of (1) 400,000 shares of Common Stock, and (2) pre-funded warrants to acquire 50,000 shares of Common Stock, subject to a 9.99% beneficial ownership limitation. The percentage reported herein is calculated based on 4,036,314 shares of Common Stock outstanding immediately after the offering, as reported in the prospectus filed by the Issuer on June 9, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The securities beneficially owned by the reporting persons consist of (1) 400,000 shares of Common Stock, and (2) pre-funded warrants to acquire 50,000 shares of Common Stock, subject to a 9.99% beneficial ownership limitation. The percentage reported herein is calculated based on 4,036,314 shares of Common Stock outstanding immediately after the offering, as reported in the prospectus filed by the Issuer on June 9, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The securities beneficially owned by the reporting persons consist of (1) 400,000 shares of Common Stock, and (2) pre-funded warrants to acquire 50,000 shares of Common Stock, subject to a 9.99% beneficial ownership limitation. The percentage reported herein is calculated based on 4,036,314 shares of Common Stock outstanding immediately after the offering, as reported in the prospectus filed by the Issuer on June 9, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The securities beneficially owned by the reporting persons consist of (1) 400,000 shares of Common Stock, and (2) pre-funded warrants to acquire 50,000 shares of Common Stock, subject to a 9.99% beneficial ownership limitation. The percentage reported herein is calculated based on 4,036,314 shares of Common Stock outstanding immediately after the offering, as reported in the prospectus filed by the Issuer on June 9, 2026.


SCHEDULE 13G



Stonepine Capital Management, LLC
Signature:/s/ Jon M. Plexico
Name/Title:Managing Member
Date:06/16/2026
Stonepine Capital, L.P.
Signature:/s/ Jon M. Plexico
Name/Title:Managing Member of the General Partner, Stonepine GP, LLC
Date:06/16/2026
Stonepine GP, LLC
Signature:/s/ Jon M. Plexico
Name/Title:Managing Member
Date:06/16/2026
Jon M. Plexico
Signature:/s/ Jon M. Plexico
Name/Title:Reporting Person
Date:06/16/2026
Exhibit Information

EXHIBIT 99 - AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G.

ATTACHMENTS / EXHIBITS

AGREEMENT REGARDING JOINT FILING OF SCHEDULE 13G

Categories

SEC Filings